The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision o...
[[abstract]]The most recent version of the European Society for Medical Oncology (ESMO) Clinical Pra...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
This article summarises expert discussion on the management of patients with hepatocellular carcinom...
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed ...
Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have m...
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common c...
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality ...
Hepatocellular carcinoma (HCC) is one of the commonest malignant tumours in the East. Although the m...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80...
Hepatocellular carcinoma (HCC), characterized by insidious onset, rapid progression, and poor treatm...
Hepatocellular carcinoma (HCC) is a highly prevalent disease in many Asian countries, accounting for...
Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80...
Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the t...
[[abstract]]The most recent version of the European Society for Medical Oncology (ESMO) Clinical Pra...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
This article summarises expert discussion on the management of patients with hepatocellular carcinom...
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed ...
Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have m...
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common c...
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality ...
Hepatocellular carcinoma (HCC) is one of the commonest malignant tumours in the East. Although the m...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80...
Hepatocellular carcinoma (HCC), characterized by insidious onset, rapid progression, and poor treatm...
Hepatocellular carcinoma (HCC) is a highly prevalent disease in many Asian countries, accounting for...
Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80...
Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the t...
[[abstract]]The most recent version of the European Society for Medical Oncology (ESMO) Clinical Pra...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
This article summarises expert discussion on the management of patients with hepatocellular carcinom...